Clinton Group’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-134,583
Closed -$12.6M 416
2017
Q3
$12.6M Buy
134,583
+116,029
+625% +$12.3M 1.38% 4
2017
Q2
$2.06M Sell
18,554
-3,481
-16% -$368K 0.21% 155
2017
Q1
$2.16M Buy
22,035
+11,560
+110% +$1.1M 0.13% 235
2016
Q4
$963K Buy
+10,475
New +$903K 0.06% 367
2016
Q3
Sell
-13,502
Closed -$1.1M 935
2016
Q2
$1.1M Buy
+13,502
New +$1.03M 0.05% 453
2016
Q1
Sell
-8,042
Closed -$572K 896
2015
Q4
$572K Sell
8,042
-7,670
-49% -$516K 0.05% 481
2015
Q3
$966K Sell
15,712
-14,045
-47% -$982K 0.09% 306
2015
Q2
$2.16M Buy
+29,757
New +$2.2M 0.3% 98
2014
Q1
Sell
-19,721
Closed -$1.06M 348
2013
Q4
$1.06M Buy
+19,721
New +$1.17M 0.35% 38
2013
Q3
Sell
-7,965
Closed -$483K 347
2013
Q2
$483K Buy
+7,965
New +$475K 0.16% 141

Other funds holding DGX

Clinton Group's DGX Position: Q4 2017 in Review

Clinton Group sold out of Quest Diagnostics (DGX) in Q4 2017, closing a stake of 134,583 shares — an estimated $12.6M sold.

Clinton Group first reported a position in DGX in Q2 2013 and held it in 10 quarters. The position peaked at $12.6M in Q3 2017. 631 funds tracked by Wall St. Rank hold DGX as of Q4 2017.

  • Clinton Group reported no remaining Quest Diagnostics position as of Q4 2017 after selling out during the quarter.
  • Clinton Group sold 134,583 Quest Diagnostics shares in Q4 2017, an estimated $12.6M.
  • Clinton Group first reported a position in Quest Diagnostics in Q2 2013 and held it in 10 quarters.
  • Clinton Group's Quest Diagnostics position peaked at $12.6M in Q3 2017.
  • 631 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2017.

Based on Clinton Group's 13F filing for Q4 2017, filed 14 Feb 2018.